PRDM16 Antibody
| Code | Size | Price |
|---|
| PSI-5555-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5555-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
PRDM16 Antibody: MEL1, LVNC8, PFM13, CMD1LL, KIAA1675, MEL1, PR domain zinc finger protein 16, PR domain-containing protein 16
Application Note:
PRDM16 antibody can be used for detection of PRDM16 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 2 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human and mouse samples and Immunofluorescence in human and mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human and mouse samples and Immunofluorescence in human and mouse samples. All other applications and species not yet tested.
Background:
PRDM16 Antibody: PRDM16 is a zinc finger transcription factor and contains an N-terminal PR domain. The reciprocal translocation t(1;3)(p36;q21) occurs in a subset of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). This gene is located near the 1p36.3 breakpoint and has been shown to be specifically expressed in the t(1:3)(p36, q21)-positive MDS/AML. The translocation results in the overexpression of a truncated version of this protein that lacks the PR domain, which may play an important role in the pathogenesis of MDS and AML. Recent studies have shown that PRDM16 normally acts as a Smad3 binding protein that may be important for the development of orofacial structures through modulation of the TGF-beta signaling pathway. Other experiments have indicated that PRDM16 controls a bidirectional cell fate switch between skeletal myoblasts and brown fat cells.
Background References:
- Mochizuki N, Shimizu S, Nagasawa T, et al. A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood2000; 96:3209-14.
- Morishita K. Leukemogenesis of the EVI1/MEL1 gene family. Int. J. Hematol.2007; 85:279-86.
- Warner DR, Horn KH, Mudd L, et al. PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic orofacial tissue. Biochim. Biophys. Acta2007; 1773:814-20.
- Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature2008; 454:961-7.
Buffer:
PRDM16 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
PRDM16 antibody was raised against a 17 amino acid synthetic peptide from near the carboxy terminus of human PRDM16.
The immunogen is located within amino acids 1120 - 1170 of PRDM16.
The immunogen is located within amino acids 1120 - 1170 of PRDM16.
NCBI Gene ID #:
63976
NCBI Official Name:
PR domain containing 16
NCBI Official Symbol:
PRDM16
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 109, 120, 140 kDa
Observed: 140 kDa
Observed: 140 kDa
Protein Accession #:
CAH71530
Protein GI Number:
55665817
Purification:
PRDM16 Antibody is affinity chromatography purified via peptide column.
Research Area:
Stem Cell
Swissprot #:
Q9HAZ2
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | PRDM16 Peptide | PSI-5555P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|